| name | Ranolazine |
| classification | Antianginal, Antiarrhythmic |
| pharmacokinetics | Ranolazine is primarily metabolized by the liver, primarily through CYP3A4. Significant drug-drug interactions are common, impacting its metabolism and potentially increasing blood concentrations of both ranolazine and the interacting drug. The drug exhibits significant accumulation in the body, leading to a prolonged elimination half-life. Absorption is variable, influenced by food, and may be delayed. Renal elimination is minimal. Specific details like peak concentrations and time to peak vary significantly based on individual patient factors. |
| suggested dosage | | male patient 25 70kg | | initial dose | 500 mg twice daily | | titration guideline | Increase to target dose gradually, titrating upward every 2 to 3 days, to a maximum of 1000 mg twice daily, based on individual tolerance. | | important note | Individual responses to ranolazine may vary. Close monitoring of blood pressure and heart rate is crucial throughout dosage adjustments. |
|
|
| indications | Ranolazine is primarily used to treat chronic stable angina, when other treatments are insufficient. It may also be used for certain specific types of heart rhythm problems (arrhythmias), but this is less common. |
| safety in pregnancy | Limited data on the safety of ranolazine during pregnancy. Consult with a healthcare provider to weigh risks and benefits if pregnancy is present or suspected. It's generally not recommended for use during pregnancy due to insufficient data. |
| safety in breastfeeding | Ranolazine may pass into breast milk, but the amount is not well-known. Consult with a healthcare provider if breastfeeding to balance potential benefits against possible risks to the infant. |
| side effects | | 1 | Headache | | 2 | dizziness | | 3 | constipation | | 4 | nausea | | 5 | vomiting | | 6 | QT prolongation (potentially leading to serious heart rhythm problems) | | 7 | increased blood pressure | | 8 | abnormal heart rhythms | | 9 | decreased heart rate | | 10 | edema (fluid retention) |
|
| alternatives | |
| contraindications | | 1 | Severe hepatic impairment | | 2 | Significant renal dysfunction | | 3 | Known hypersensitivity to ranolazine or any of its components | | 4 | Use with strong CYP3A4 inhibitors (may significantly increase ranolazine levels) | | 5 | Concomitant use with certain drugs that may prolong the QT interval (e.g., certain antiarrhythmics) |
|
| interactions | Ranolazine has significant interactions with many medications, particularly those metabolized by CYP3A4. Consult a pharmacist or healthcare provider about potential interactions with any other medications the patient is taking, including over-the-counter medications. |
| warnings and precautions | | 1 | Monitor blood pressure and heart rate closely, especially during dose titration. | | 2 | Caution in patients with pre-existing heart conditions. | | 3 | Caution when used with other drugs that can prolong the QT interval. | | 4 | Monitor for signs of liver problems (e.g., jaundice, abdominal pain). | | 5 | Regular blood tests may be needed to monitor for potential side effects. |
|
| additional informations | Ranolazine can increase the concentration of other drugs in the body; thus it's important to make sure all medications are taken as prescribed and to inform your doctor about everything. Specific dosage adjustments and additional monitoring may be required based on individual patient factors, such as existing health conditions. |
| patient profile | |
